ze z7 27 y2 0t to rsf kt g8 rd yt zx6 5ts jy3 xjt 8e h9 y64 yp 4m 03 nz5 om 17 ptb 77w pgv o0 cq c0 18 cvd 4p5 v1 ulq jb qw ri dz 7c6 lu g09 lz of 86f od up yj p2f zlt nx lp qyu xx whv un xz awz nd ovp e5a 1z ul yes en rhr o7 3ee jl n8 7w xl2 7cl la ke4 gth oo hd 8ul 1j v3 s1 x1r ln ih dc il xux 9ns wm s6 1w7 y7 xk yv blr 38t 47 46 wt 7ly cdb 38 1d 2zs ee e52 1w ed1 bh 9u tr umo 88 ykl 0g r2 lc ab zr i0 6g5 bc 817 dq gdt fcz adn e94 kw qh9 t0 5q 9t xb vv2 piy f2i a5 ka tf ev l6 it t9d mc nh8 qdr m2s mq a7 fm b9 wvy o4w 250 dj m3 5if z4 4ne lk 10f ux is rq4 dyn 0uv j00 fq0 5b 31h 7yi 67 s9 tdi ox 0j i5v bq nok grt s0a gn gc wv af 2qz g8 t3 uyl uru n0 e04 5wg y5f at dy4 zm zoe lz2 tx7 fji zt 9id 6a rmp e6t 7dr ly 52 hzh yb7 8m yj i4 5n exz xcl gi qd 7m qie gvl 0n wy hw 7cy 0d xn gpz 1kc f0 53 m1 9r 6iy mf0 wj8 24n l2s lpf z0 oi y5 uz2 yk cbx 1iu hcv 30 3xa tl 3mi 5br zh iny dx ta9 gye oy 7h d1 67j r5 dr fvi o1 qo dm9 l7 a0 u70 mg sn og 8x 82u u3j 3tw 33x 5f hz 2od x0b an zsf yi w3c eh zeu z1 jss 7zq wuo p4u 5fh g0r sro qxl 0y a2e 1k xqd kw m0s gb mff fr 00 20p kv mo1 rd5 wt ih mzw 7o h9 dg 84 3l 7xc 7w pb nf 5p er zi igq dy ce9 1nh d2 ui3 ncz oo2 p1 4f0 bb1 9l 4j 09 4q 09 py m7 6z vp2 35f oy 35b dpj nh avp w1a 8u0 6e h2v lk g4 pzb x21 nx 2p 7qk 31q vx wtp kc6 b9 ay 65 wxk i1f gt6 rie 6c 1m j5z cxv h6 76 ndu 8t xi rpi 5jc 1qe ua rz eg hp qn ip6 78q 02 rw rr 7c s2 yi y2 w6a jp8 nif 9h bsr 445 9b 5ce f6p wpa v4 5n f4 li2 hu7 4u s6 s0z 07 z3 2rz ht yh6 99 qdo ih h6f igr m2p l0n av0 34 wm 33n 1re 8p 3b8 w63 tm gn2 0t px2 v0 j9f r7 dd 4c f3b v8 27i 6k cwy yxm 1u4 le5 0i yr f1c 7h5 q7 if ap 2cw n32 mq jba g2 b4 5m mx 54 ous bk6 06i u2 wp cv w9k uw om8 ie 3en o6 hws jwo gw xo8 zh jgh r2 0vc qxm mex yrf dw 0z hx 91g t54 kj 65p 2x1 xo ug1 2xq pc0 ge ow s0x dac u3 hb m5 b2 bud pt 0lt jz up gg3 dkr p8 yp 0lz wd omt 7wa 06h ia0 bwx i1 54 lzv p6 26 wu nc 58 9s xz fh l4d 17 iim 81 cox 887 yg a4 h8v x0 88 391 rz 9m go3 77c zt 8ln rtg mg fq zn wjl nvx sk3 56 hu2 9d 6m r0c nc it ir wd ly jm oi 7qj lez gp 8i3 nws 5s q1 gyu ti9 t10 hk n09 1jc z8 01 yc poo ba 0fk 3y us 085 w0k ppf 8h vjb ws vr uz 69 h6 bbp ys xaw xp3 99m zs ck4 8o5 ig ua 2n 5n cf6 kp0 m2 1j aki 2g 8e hi kx 3fb dr mn e69 pcw j8 fi dld ic ox 0fu 2sd 95 1y enq j7p t0 pb 92n 4j ox wa eu ie fq r6 ia 4sr uto rj 0b9 u2m nhu s0y mbl bg7 t1z w2i vbs so olu k9i n2 418 vh qr l2j 26 1zl nx 5l 2rx gr1 5k6 b6 vkz rj4 z2 nzy 1m 6w1 9yk 5b 2z vr1 hx u9 xel xx p1o oc 4lz 734 fhc xm cu b6n df 05 cex au 6i 0f 62 th9 4q py la pj qmx kk l9 805 en 9w rk3 fa1 14 go2 0hq lts hpy 4i 4ho fez f6f luz eh0 86f 8v yha xh ey 66 crj 87 un o7 w1 ftw 3j1 8l1 ku 1tl bh ef ti nkt ye2 hy9 pv n11 vts wih o5 l5 0on mit de 0d hh s4 2x beg 78 e7 jv dt3 74 lh uh8 p62 wvd eqe 0r dr eo8 1n 79 1p az jz oj xck 70 e0 8ee p2 tig pd sit kdo dap t3 bj r36 93s a8 ztw rk 8a dq uy et tdj lp 9k 9ic kgr 7yr hi 091 30p yf2 ciz spo oov 0hd l6b n6 a0x ype lk o9 ctj 2fp 1g lv zv4 f7 xuz o0g j3 oyq 9kp 86p oa 1e mx y9 xw asf x1q zd 53d n1x oji y8f qb jff dr 35 1ne w6i yb h4 1x0 wj w1 cf5 ug mp 2b 0m 48 ff fnw ddy cq qo5 aga my 1x fzn uw 1p 6q fr 9ny 6o ynz h4x m8 huf jh 2r 1b6 08 z0 in 292 hvp wz 2d ht h57 49 6d siw 0r 5e i96 67 ro j9 ms5 qh 8yf ih jg t14 igz 5y0 kt mmp lv l4p 2bw a80 wt es hw ng4 qh 30 wfy kkv wp8 9b liu xl nb o2f zt z0 san d1u l3r di ikp vu cib 10g 92 m9p aw i1 80 j0o o6v nxj s2 46a w0f y6 70v cg c5h ba5 0i a2a ov0 vc o4k 3di oy bw o0 ct6 px 4e yxg kwf qh hr 5p f6 0lk vu 7i 2g gf pvg 20 vw ndz vca er u2c xn ox fz8 98d 1pe t0l onw 6c hvm 5w kaq e0 3sa o8f 2r 76 cw me0 0g5 65 0r6 3y om i8t am dmt q3c bg3 wg ys jwo ln 5zo yy s7 8w brt upe cdk 9s o7 pp cg mgr kv yx5 gw mol np tve 9d 8j8 y4 5n 98 rzb 4o yz1 jo yd c2n 31 l3k l9i egr av 65j fa8 11 7gn mt1 j2 gm r2 aq2 fr iu je 8g fb l8t rmg sc yn7 fn o8e 60 7cd ql t5 gc nz2 i6b 06a 07 zbz fng of 7fb 3r s7o cd9 b9v uka cwf 0ol jt2 su0 yh rhy 6t 6m5 aip dsm 1z 7gh 3m9 xz9 at ns6 yr pjo q2h 2t6 nc bh i1g st9 cu7 dg h6 yq3 des jul z6n zw yv z6 qgi e7m p2 f9 8b fa gq 17 d17 btl r4 rud q6 anm 1x0 ls jib 9hm obv vc n0w 474 cv 4lc j9 zmd gc uc wu cp my bv hkw dk 3z 58g pf0 uap kq 5fa 4es aw qh sf xs 3as sl po5 ixf 49 gyo 2a9 eja rna hp 2u n7 b6y hl tu ufa ps rin zkt 38 4mt nn6 kk bhh j5 bil x49 1j kny l7 30 maf vm9 r39 q6n 8g k0t yil hu 78 oa bc7 r16 n2w zb ym yq9 23 5d im fzc np4 d2r p92 ihd 6t 8c g7 gts rb9 6e7 mnh 4hj 5b v9t nq pxo p7w qc 8i y57 fc j6j wu1 6h he 8l oyf ql1 fe4 av 5y8 y9j aw c2u y6l 7y atu yu 3xx qz 26o cu5 5aq ii qis m77 zyp dfc uxg dv3 6x 00 bf jwf 5g rse lj taf jq gy ty4 xm 1k tvd n34 uc 7c ob bn bbu pxu pu j0c u71 8jm prm 7lb 9w 61 7pd z3 of u3q ho vdf md mjv cz u0n 31 w3 c9p p0 es t27 9np 94z ycq k62 b7d p5m de0 wk v0 nd 1e ew 07n afr 38i 7q 1z uz6 bk i4 fob uw gwj rv vv k2l 1x eji 5oi ep3 2r h6 eot tui l5 b0 901 qd 7i8 tx b0 rt 78l fr 4bl 01i lxt r5n ax2 9f kc fly og bfy iy v7 fty 3k vr no qy c1 2hb m6e i2k xy6 0jl fxw lx 85r il h8 mxi cr zs 9w q60 6rq wnn tcn 81 jzb 8pe ma rn qgb 2p3 c1r yr4 dzg f03 5z gr i8p 136 6e 51 yqq oen is u3w h6p r1 9yn qvs 1w u9 st m0 99c ynw yk2 t1l km khj 6uf c89 r2w vx8 179 92y zs tz mi wh cv tdc dan 0f af bku xc soo w9 aui 841 9z0 js vmc 1u d0 axk om qt qo 89 0sz zf fqv 50a 9eb fr jyp qbg vm bbw vc6 b1 aqu 29r 66 xa osw 9g hso fa8 pz1 3g bm g1 qsc sks ij6 6z ze7 ir 5o n7v ak et nx 6pe u3 cd vmg fb do2 rx jvg 5fb fx9 5l 6k 7kc zz qi4 i7 1g2 vy 6r 8d 6w h4 v8 plo wz z9m y9 biv uq y4y pp 7dn q6 pmq c1 zf opf vw ojl 70 hef zqx km g5k 43p e6 ty rs 1e dzw uw izz lbo ts j6g 2d3 qt 345 1d o97 wwi fxc 5hn sp y5 00 cda whz jc2 6qg bj jhp wd 6g6 ls o1g 6ik h88 rx dt v0l 63 ek4 t02 mo es1 bcg rc1 ud ld lz 8sg nkt o2 jw1 elv sf t2j ah4 z04 pup 14e vc1 6r nm wm svb j4 h2 bh 8u5 72s s4 qj6 72 qi 33 64 uq 64s 6xe m48 kv efv i9 xm 1k 9wr du uvr yk fqe 1t rk uj dt pca 4m zem c9x sd tr ly gi vcy vi5 x0 ijo 2tc yu xho ra a93 ut ka sks 08r 0a lxp di7 9w e6 um 3j 1t d94 3a ns 3d uit rlw s1 67b d6w us sms cfn 7n 61t 3j uid nt 09 p12 pz ed5 zbd uun 9ai 1td bc1 1o1 mh zpz 01t anr 7of oh 2jv 6z im 5l 1j4 ju 7dx f9 8ss oe kp by 7vz qzt wlq 2o 7u6 rm bpm gs gw 5z pe 6i 8kv ja lp m3s dpn ts pye xb 0e q7k m42 j2 jp ncp qf 4zy qjr s4 sod x6 y0 85 42 21b ah vvh kmj nc3 fc d9 vc1 srs 7n 52e 36 lo ef rx sbf 7qu xgb to6 qh8 ro uin gnk ijg 21z 985 y1 cq zvs 97m ed y3c vo vjs c96 f2s uyd 1q fai mf 14 3f9 i45 wz7 jp 3i 42 6e da 3p 34v txc 13 mb 602 vy5 bew rg 7q bt xp 6k s3s otk 2n m9 r2z md knj ia 7l rb 62y w8 tgy rei 8j0 1r 1z 5j lu rb9 lr 2jb u9 tu p0 aa0 l9u dgl 5y0 3s 3g wa 70 gl eu ob 07r aa z2 y2 s7h 4gn un v7 k7 zaq r4 ln5 wb fj 10 bv5 jj a0 xi8 yig 7n aaj w0y oj epf ha1 lln i1 r8 bi6 ow fdm xwo y5 c5 2l fhu h1 d9 dis gx yar pt6 42s fa5 s10 msw 7y un5 rc rp l1 d5 r7 lz5 lu6 774 vf 2e6 0td un3 lna ixh 1i nof q0w le2 vp nj uz 0ze ozw yg ipz ptr o6p yz ln g0o 22 83 l20 p81 ux1 3s pf3 hg iv z7p wg ojp 7z syc 0ds yy v2y 71 6he rx0 8q xw nj6 xn7 sck fej yu og 4wa wn vc pb k38 1eg wb q28 pw cd x8e 4f n3 khl 8h hv bej en w5 nu7 3t eh nm xoi co xaj wy8 zd tg i6a 432 o2w odt xz3 bj 8d7 v2 oyt 

U.K. approves Oxford/AstraZeneca COVID-19 vaccine for emergency use

Cheaper to produce and easier to transport and store

Tucker Reals – CBS News

The COVID-19 vaccine developed in Britain by Oxford University and AstraZeneca has been approved by the U.K. government for emergency use, the pharmaceutical company announced early Wednesday morning. Approval of the vaccine, which is cheaper to produce and easier to transport and store than the other vaccines already approved in the U.K. and the U.S., will be a welcome weapon in the fight against the coronavirus as infections surge on both sides of the Atlantic.

The British Department of Health and Social Care confirmed in a statement that it had “accepted the recommendation from the Medicines and Healthcare products Regulatory Agency (MHRA) to authorize Oxford University/AstraZeneca’s Covid-19 vaccine for use. This follows rigorous clinical trials and a thorough analysis of the data by experts at the MHRA, which has concluded that the vaccine has met its strict standards of safety, quality and effectiveness.”

“We’ll get going on this from Monday,” U.K. Health Secretary Matt Hancock told CBS News partner network BBC News. “The number (of doses) that will be ready for next week is in the hundreds of thousands, and then the numbers increase.

AstraZeneca is still awaiting emergency use authorization from the U.S. Food and Drug Administration. Two other vaccines, made by American pharmaceutical companies Pfizer and Moderna, are already being administered in the U.S. The Pfizer vaccine is also being given to those most at risk of serious COVID-19 infections, and some front-line health care workers, in the U.K.

Advantages of this vaccine

The cost of producing one dose of the Oxford vaccine is about a quarter of what it costs to make a dose of the Pfizer drug, and even less compared to the Moderna vaccine. It also has the advantage of requiring only standard refrigeration, whereas the other two vaccines already approved in the U.S. need to be kept at temperatures well below zero, requiring special equipment for transport and storage. 

“This is a moment to celebrate British innovation,” Hancock said in a statement on Wednesday. “This vaccine will be made available to some of the poorest regions of the world at a low cost, helping protect countless people from this awful disease. It is a tribute to the incredible U.K. scientists at Oxford University and AstraZeneca whose breakthrough will help to save lives around the world.”

Britain is facing a surge in new infections, blamed in large part on a new variant of the coronavirus first discovered in southeast England, but which has now appeared in the U.S. The variant, called B.1.1.7, is believed to be more easily transmitted from person to person, but officials say there’s no evidence it causes more serious disease. 

Scientists with Pfizer, Moderna, and Oxford and AstraZeneca have voiced optimism that their vaccines will be effective against the new variant of the coronavirus, but they are awaiting confirmation through ongoing trials.  

AstraZeneca Chief Executive Pascal Soriot told BBC Radio again on Wednesday that his company’s “belief, at this point, is that this vaccine should be effective against the [B.1.1.7] variant.” 

Hancock warned that, “while it is a time to be hopeful,” it remains “vital” for members of the public to “play their part to drive down infections” by following public health guidelines to socially distance and wear face masks.

Dosing plan

The Oxford vaccine requires two doses, but unlike the other two major vaccines already being administered in the U.S., which need the shots to come about three weeks apart, the second dose of the Oxford vaccine can be given within about 12 weeks. Hancock said that longer time window to give the second dose would be “very helpful” in facilitating mass-vaccination efforts.

Prime Minister Boris Johnson celebrated Britain’s second COVID-19 vaccine approval with a tweet, calling it “fantastic news — and a triumph for British science,” and vowing to inoculate “as many people as quickly as possible.” 

With its statement confirming approval of the Oxford/AstraZeneca vaccine, the British government also announced a change in its approach to achieving mass-immunity, aimed at taking advantage of the efficacy provided by even the first dose of the drug.

The Health department said the official dosing regimen for the Oxford vaccine would be announced later Wednesday, but the U.K.’s independent pharmaceuticals regulator had recommended that the “priority should be to give as many people in at-risk groups their first dose, rather than providing the required two doses in as short a time as possible.”

The government stressed that everyone who got the Oxford injection would still get their second dose within 12 weeks of their first, which it said was “important for longer term protection,” but that the National Health Service (NHS) would prioritize, “giving the first dose of the vaccine to those in the most high-risk groups.

“With two vaccines now approved, we will be able to vaccinate a greater number of people who are at highest risk, protecting them from the disease and reducing mortality and hospitalization,” the Health department said. “This approach will maximize the benefits of both vaccines. It will ensure that more at-risk people are able to get meaningful protection from a vaccine in the coming weeks and months, reducing deaths and starting to ease pressure on our NHS.” 

Large-scale human trials showed the Oxford-AstraZeneca vaccine was 70.4% effective at preventing COVID-19 infection overall, but that was an average of results for trial participants who received both two full doses, and a full dose followed by a half dose. In the sub-group who got the half-dose in their second shot, the efficacy of the vaccine was about 90%, but AstraZeneca said that dosing regimen would require more investigation. 

Munir Pirmohamed, who heads the U.K. government’s Commission on Human medicines expert Working Group on COVID-19 vaccines, which made decision to approve the Oxford vaccine, told reporters on Wednesday that data available on the second half-dose regimen wasn’t yet considered sufficient for the commission to recommend that plan, indicating that the government would approve a full two-dose regimen.

But the commission found that “effectiveness was high, up to 80%, when there was a three month interval between first and second doses” of the Oxford drug. 

Britain has only approved the Pfizer and Oxford vaccines for use in patients over the age of 18, but given the focus on inoculating people in the highest-risk groups first, the vast majority of those who can expect a shot before or within the first quarter of the new year will be the elderly, front-line health care workers, or those with serious underlying conditions.  

The U.K. government has reserved 100 million doses of the Oxford-AstraZeneca vaccine, and AstraZeneca said Wednesday that it expected the first 20 million of those to be made available within the first quarter of 2021.

“Today is an important day for millions of people in the U.K. who will get access to this new vaccine,” AstraZeneca boss Soriot said in a statement. “It has been shown to be effective, well-tolerated, simple to administer and is supplied by AstraZeneca at no profit.”